- Home » News and Events
NEWS & EVENTS
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Towards Industrialization of Induced Pluripotent Stem Cell-based Therapies
Jun 24, 2021
Catalent today announced that it has reached an agreement to acquire RheinCell Therapeutics GmbH, a developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs).
Catalent Acquires Additional Facility at its Gosselies, Belgium Campus for Commercial-Scale Plasmid DNA Manufacturing
May 6, 2021
The facility will accommodate Catalent’s new commercial-scale plasmid DNA (pDNA) manufacturing and will provide the opportunity for the immediate growth of Catalent’s pDNA service offering.
AavantiBio and Catalent Announce Partnership to Support Development and Manufacturing of Gene Therapies for Rare Genetic Diseases
Apr 27, 2021
AavantiBio and Catalent today announced a partnership to support the development and manufacturing of AavantiBio’s gene therapies, including its lead program in Friedreich’s Ataxia (FA).
Catalent Biologics Completes Madison Facility Expansion to Double Clinical and Commercial Drug Substance Capacity
Apr 13, 2021
Catalent has completed the expansion of two new suites at its biologics drug substance development and manufacturing facility in Madison, Wisconsin, and has now commenced work on customer programs.
Moderna and Catalent Announce Long-Term Strategic Collaboration for Dedicated Vial Filling of Moderna’s COVID-19 Vaccine and Clinical Portfolio
Apr 6, 2021
Moderna and Catalent today announced the expansion of their strategic partnership to dedicate a new high-speed vial filling line for the manufacture of the Moderna COVID-19 Vaccine at Catalent’s facility in Bloomington, Indiana.
Catalent Expands Partnership with Johnson & Johnson to Significantly Increase Capacity for Sterile Manufacturing and Packaging of COVID-19 Vaccine in Italy
Mar 17, 2021
Catalent today announced Catalent Biologics will significantly increase the manufacturing capacity for large-scale commercial supply of Janssen’s COVID-19 vaccine at Catalent’s manufacturing facility in Anagni, Italy.
Catalent joins the EuropaBio 25th Anniversary in 2021
Mar 9, 2021
EuropaBio today announced that Catalent has joined EuropaBio’s 25th Anniversary Celebration Programme as a major sponsor.
Catalent to Acquire Delphi Genetics and Launch US Plasmid Manufacturing Site to Establish Global pDNA Development and Manufacturing Capabilities
Feb 23, 2021
Together, the addition of pDNA technology and production capabilities marks a significant milestone for Catalent Cell & Gene Therapy.
Catalent Signs Development and Manufacturing Agreement with Trizell for Macrophage-based Advanced Cell Therapy
Feb 8, 2021
Catalent today announced that it had signed an agreement with Trizell GmbH, to support the manufacturing of Trizell’s Phase 1 cell therapy for the treatment of micro- and macroangiopathies.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.